| Outcome Measures: |
Primary: Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline, The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM), At baseline, 6 months of intervention | Secondary: Number of Participants With Hypoglycemia, Severe hypoglycemia-documented glucose \<50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel., 26 weeks|Weight Change During Trial, Weight in kg at 26 weeks minus weight at baseline., Baseline vs 26 weeks | Other: HbA1C Levels, % of glycosylated hemoglobin in whole blood at 26 weeks, Baseline vs 26 weeks
|
| Locations: |
So Calif. Permanente Medical Group, San Diego, California, 92109, United States|University of Miami, Miami, Florida, 33136, United States|Atlanta Diabetes Associates, Atlanta, Georgia, 30309, United States|Joslin Diabetes Center, Boston, Massachusetts, 02215, United States|International Diabetes Center, Minneapolis, Minnesota, 55416, United States|Washington University, Saint Louis, Missouri, 63110, United States|Kaledia Health of Western New York, Buffalo, New York, 14209, United States|Diabetes Care Center, Durham, North Carolina, 27713, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|University of Vermont, Colchester, Vermont, 05446, United States|University of Washington, Seattle, Washington, 98105, United States|Washington State University Spokane, College of Pharmacy Spokane WA 99202 USA, Spokane, Washington, 99202, United States
|
